<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet href="/rss.css" type="text/css"?>
<rdf:RDF xmlns="http://purl.org/rss/1.0/"
    xmlns:cc="http://web.resource.org/cc/"
    xmlns:dc="http://purl.org/dc/elements/1.1/"
    xmlns:extra="http://www.w3.org/1999/xhtml"
    xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/"
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#">
    <channel rdf:about="http://www.biomedcentral.com/feeds/latestarticles/journal?journal=bmcearnosethroatdisord&amp;quantity=&amp;format=rss&amp;version=">
        <title>BMC Ear, Nose and Throat Disorders - Latest Articles</title>
        <link>http://www.biomedcentral.com/bmcearnosethroatdisord/</link>
        <description>The latest research articles published by BMC Ear, Nose and Throat Disorders</description>
        <dc:date>2012-03-26T00:00:00Z</dc:date>
        <items>
            <rdf:Seq>
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1472-6815/12/4" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1472-6815/12/3" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1472-6815/12/2" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1472-6815/12/1" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1472-6815/11/9" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1472-6815/11/8" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1472-6815/11/7" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1472-6815/11/6" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1472-6815/11/5" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1472-6815/11/4" />
                            </rdf:Seq>
        </items>
                 <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </channel>
        <item rdf:about="http://www.biomedcentral.com/1472-6815/12/4">
        <title>Cortisol suppression and hearing thresholds in tinnitus after low-dose dexamethasone challenge</title>
        <description>Background:
Tinnitus is a frequent, debilitating hearing disorder associated with severe emotional and psychological suffering. Although a link between stress and tinnitus has been widely recognized, the empirical evidence is scant. Our aims were to test for dysregulation of the stress-related hypothalamus-pituitary adrenal (HPA) axis in tinnitus and to examine ear sensitivity variations with cortisol manipulation.
Methods:
Twenty-one tinnitus participants and 21 controls comparable in age, education, and overall health status but without tinnitus underwent basal cortisol assessments on three non-consecutive days and took 0.5 mg of dexamethasone (DEX) at 23:00 on the first day. Cortisol levels were measured hourly the next morning. Detection and discomfort hearing thresholds were measured before and after dexamethasone suppression test.
Results:
Both groups displayed similar basal cortisol levels, but tinnitus participants showed stronger and longer-lasting cortisol suppression after DEX administration. Suppression was unrelated to hearing loss. Discomfort threshold was lower after cortisol suppression in tinnitus ears.
Conclusions:
Our findings suggest heightened glucocorticoid sensitivity in tinnitus in terms of an abnormally strong glucocorticoid receptor (GR)-mediated HPA-axis feedback (despite a normal mineralocorticoid receptor (MR)-mediated tone) and lower tolerance for sound loudness with suppressed cortisol levels. Long-term stress exposure and its deleterious effects therefore constitute an important predisposing factor for, or a significant pathological consequence of, this debilitating hearing disorder.</description>
        <link>http://www.biomedcentral.com/1472-6815/12/4</link>
                <dc:creator>Veerle Simoens</dc:creator>
                <dc:creator>Sylvie Hebert</dc:creator>
                <dc:source>BMC Ear, Nose and Throat Disorders 2012, null:4</dc:source>
        <dc:date>2012-03-26T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1472-6815-12-4</dc:identifier>
                            <dc:title>DEX suppresses cortisol in tinnitus patients</dc:title>
                            <dc:description>Suppression of stress-regulated cortisol levels and reduction in hearing discomfort in Tinnitus patients treated with Dexamethasone (DEX),  highlights the importance of stress as a predisposing factor for, and consequence of, this hearing disorder.</dc:description>
                <prism:require>/content/figures/1472-6815-12-4-toc.gif</prism:require>
                <prism:publicationName>BMC Ear, Nose and Throat Disorders</prism:publicationName>
        <prism:issn>1472-6815</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>4</prism:startingPage>
        <prism:publicationDate>2012-03-26T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1472-6815/12/3">
        <title>Effectiveness of conventional versus virtual reality based vestibular rehabilitation in the treatment of dizziness, gait and balance impairment in adults with unilateral peripheral vestibular loss: a randomised controlled trial</title>
        <description>Background:
Unilateral peripheral vestibular loss results in gait and balance impairment, dizziness and oscillopsia. Vestibular rehabilitation benefits patients but optimal treatment remains unkown. Virtual reality is an emerging tool in rehabilitation and provides opportunities to improve both outcomes and patient satisfaction with treatment. The Nintendo Wii Fit Plus (R) (NWFP) is a low cost virtual reality system that challenges balance and provides visual and auditory feedback. It may augment the motor learning that is required to improve balance and gait, but no trials to date have investigated efficacy.
Methods:
In a single (assessor) blind, two centre randomised controlled superiority trial, 80 patients with unilateral peripheral vestibular loss will be randomised to either conventional or virtual reality based (NWFP) vestibular rehabilitation for 6 weeks. The primary outcome measure is gait speed (measured with three dimensional gait analysis). Secondary outcomes include computerised posturography, dynamic visual acuity, and validated questionnaires on dizziness, confidence and anxiety/depression. Outcome will be assessed post treatment (8 weeks) and at 6 months.DiscussionAdvances in the gaming industry have allowed mass production of highly sophisticated low cost virtual reality systems that incorporate technology previously not accessible to most therapists and patients. Importantly, they are not confined to rehabilitation departments, can be used at home and provide an accurate record of adherence to exercise. The benefits of providing augmented feedback, increasing intensity of exercise and accurately measuring adherence may improve conventional vestibular rehabilitation but efficacy must first be demonstrated.Trial registrationClinical trials.gov identifier: NCT01442623</description>
        <link>http://www.biomedcentral.com/1472-6815/12/3</link>
                <dc:creator>Dara Meldrum</dc:creator>
                <dc:creator>Susan Herdman</dc:creator>
                <dc:creator>Roisin Moloney</dc:creator>
                <dc:creator>Deirdre Murray</dc:creator>
                <dc:creator>Douglas Duffy</dc:creator>
                <dc:creator>Kareena Malone</dc:creator>
                <dc:creator>Helen French</dc:creator>
                <dc:creator>Stephen Hone</dc:creator>
                <dc:creator>Ronan Conroy</dc:creator>
                <dc:creator>Rory McConn Walsh</dc:creator>
                <dc:source>BMC Ear, Nose and Throat Disorders 2012, null:3</dc:source>
        <dc:date>2012-03-26T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1472-6815-12-3</dc:identifier>
                                <prism:require>/content/figures/1472-6815-12-3-toc.gif</prism:require>
                <prism:publicationName>BMC Ear, Nose and Throat Disorders</prism:publicationName>
        <prism:issn>1472-6815</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>3</prism:startingPage>
        <prism:publicationDate>2012-03-26T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1472-6815/12/2">
        <title>Gender differences in patients with dizziness and unsteadiness regarding self-perceived disability, anxiety, depression, and its associations</title>
        <description>Background:
It is known that anxiety and depression influence the level of disability experienced by persons with vertigo, dizziness or unsteadiness. Because higher prevalence rates of disabling dizziness have been found in women and some studies reported a higher level of psychiatric distress in female patients our primary aim was to explore whether women and men with vertigo, dizziness or unsteadiness differ regarding self-perceived disability, anxiety and depression. Secondly we planned to investigate the associations between disabling dizziness and anxiety and depression.MethodPatients were recruited from a tertiary centre for vertigo and balance disorders. Participants rated their global disability as mild, moderate or severe. They filled out the Dizziness Handicap Inventory and the two subscales of the Hospital Anxiety Depression Scale (HADS). The HADS was analysed 1) by calculating the median values, 2) by estimating the prevalence rates of abnormal anxiety/depression based on recommended cut-off criteria. Mann-Whitney U-tests, Chi-square statistics and odds ratios (OR) were calculated to compare the observations in both genders. Significance values were adjusted with respect to multiple comparisons.
Results:
Two-hundred and two patients (124 women) mean age (standard deviation) of 49.7 (13.5) years participated. Both genders did not differ significantly in the mean level of self-perceived disability, anxiety, depression and symptom severity. There was a tendency of a higher prevalence of abnormal anxiety and depression in men (23.7%; 28.9%) compared to women (14.5%; 15.3%). Patients with abnormal depression felt themselves 2.75 (95% CI: 1.31-5.78) times more severely disabled by dizziness and unsteadiness than patients without depression. In men the OR was 8.2 (2.35-28.4). In women chi-square statistic was not significant. The ORs (95% CI) of abnormal anxiety and severe disability were 4.2 (1.9-8.9) in the whole sample, 8.7 (2.5-30.3) in men, and not significant in women.
Conclusions:
In men with vertigo, dizziness or unsteadiness emotional distress and its association with self-perceived disability should not be underestimated. Longitudinal surveys with specific pre-defined co-variables of self-perceived disability, anxiety and depression are needed to clarify the influence of gender on disability, anxiety and depression in patients with vertigo, dizziness or unsteadiness.</description>
        <link>http://www.biomedcentral.com/1472-6815/12/2</link>
                <dc:creator>Annette Kurre</dc:creator>
                <dc:creator>Dominik Straumann</dc:creator>
                <dc:creator>Christel van Gool</dc:creator>
                <dc:creator>Thomas Gloor-Juzi</dc:creator>
                <dc:creator>Caroline Bastiaenen</dc:creator>
                <dc:source>BMC Ear, Nose and Throat Disorders 2012, null:2</dc:source>
        <dc:date>2012-03-22T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1472-6815-12-2</dc:identifier>
                                <prism:require>/content/figures/1472-6815-12-2-toc.gif</prism:require>
                <prism:publicationName>BMC Ear, Nose and Throat Disorders</prism:publicationName>
        <prism:issn>1472-6815</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>2</prism:startingPage>
        <prism:publicationDate>2012-03-22T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1472-6815/12/1">
        <title>Canadian guidelines for rhinosinusitis: practical tools for the busy clinician</title>
        <description>Acute bacterial rhinosinusitis (ABRS) and chronic rhinosinusitis (CRS) frequently present in clinical practice. Guidelines for management of these conditions have been published extensively in the past. However, a set of guidelines that addressed issues specific to the Canadian environment while offering clear guidance for first-line clinicians was needed, and resulted in the recent publication of Canadian clinical practice guidelines for ABRS and CRS. In addition to addressing issues specific to Canadian physicians, the presented guidelines are applicable internationally, and offer single algorithms for the diagnosis and management of ABRS and CRS, as well as expert opinion in areas that do not have an extensive evidence base. This commentary presents major points from the guidelines, as well as the intended impact of the guidelines on clinical practice.See guidelines at: http://www.aacijournal.com/content/7/1/2</description>
        <link>http://www.biomedcentral.com/1472-6815/12/1</link>
                <dc:creator>Shaun Kilty</dc:creator>
                <dc:source>BMC Ear, Nose and Throat Disorders 2012, null:1</dc:source>
        <dc:date>2012-02-01T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1472-6815-12-1</dc:identifier>
                                <prism:require>/content/figures/1472-6815-12-1-toc.gif</prism:require>
                <prism:publicationName>BMC Ear, Nose and Throat Disorders</prism:publicationName>
        <prism:issn>1472-6815</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>1</prism:startingPage>
        <prism:publicationDate>2012-02-01T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1472-6815/11/9">
        <title>Single intraoperative intravenous Co-amoxiclav versus postoperative full oral course in prevention of postadenotonsillectomy morbidity: A randomised clinical trial.</title>
        <description>Background:
Adenotonsillectomy results in postoperative morbidity which otolaryngologists attempt to reduce by use of antibiotics. The regimes used as quite varied with some opting for a full oral course postoperatively while others prefer prophylactic doses. This randomised clinical trial done in Kenyatta National Hospital, Kenya had the aim of comparing the efficacy of Co-Amoxiclav given as a single intravenous dose with a full oral course in the prevention of post adenotonsillectomy morbidity.
Methods:
126 patients below 12 years scheduled to undergo adenotonsillectomy were randomised into two groups. 63 were given a single intravenous dose of Enhancin [Co-Amoxiclav] at induction while the remaining half received a five days oral course of the same postoperatively. All received oral Pacimol [Paracetamol] in the postoperative period. Analysis was done and comparison made between the two groups with regards to pain, fever and diet tolerated in the postoperative period with a follow up period of seven days.
Results:
There was no statistical significant difference between the two groups with regards to postoperative pain, fever and diet tolerated. All had a P-value &gt; 0.2. Postoperative pain was highest in the first postoperative day and reduced progressively to the lowest level on the 7th postoperative day. As pain reduced, patients were able to tolerate a more solid diet with all but 6 tolerating their usual diet. 4 patients developed fever in the 1st postoperative day which did not progress to the next day. One patient had fever on the 4th and 7th postoperative day and was admitted in the paediatrics&apos; ward with a chest infection. All these patients with history of fever were in the group that was on oral postoperative Co-Amoxiclav.
Conclusion:
A single intraoperative dose of Co-Amoxiclav given intravenously at induction was found to be just as effective as a full oral course of the same given postoperatively in the prevention of post adenotonsillectomy morbidity. The prophylactic dose is favoured over the later as it is cheaper, ensures compliance and relieves off the need for refrigeration of the oral suspension as not all have access to refrigeration in low economy countries as ours.Trial registrationClinicalTrials.gov: NCT01267942</description>
        <link>http://www.biomedcentral.com/1472-6815/11/9</link>
                <dc:creator>Musyoka Mutiso</dc:creator>
                <dc:creator>Isaac Macharia</dc:creator>
                <dc:source>BMC Ear, Nose and Throat Disorders 2011, null:9</dc:source>
        <dc:date>2011-09-30T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1472-6815-11-9</dc:identifier>
                                <prism:require>/content/figures/1472-6815-11-9-toc.gif</prism:require>
                <prism:publicationName>BMC Ear, Nose and Throat Disorders</prism:publicationName>
        <prism:issn>1472-6815</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>9</prism:startingPage>
        <prism:publicationDate>2011-09-30T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1472-6815/11/8">
        <title>Etiological profile and Treatment outcome of Epistaxis at a Tertiary care hospital in Northwestern Tanzania: A prospective review of 104 cases</title>
        <description>Background:
Epistaxis is the commonest otolaryngological emergency affecting up to 60% of the population in their lifetime, with 6% requiring medical attention. There is paucity of published data regarding the management of epistaxis in Tanzania, especially the study area. This study was conducted to describe the etiological profile and treatment outcome of epistaxis at Bugando Medical Centre, a tertiary care hospital in Northwestern Tanzania.
Methods:
This was a prospective descriptive study of the cases of epistaxis managed at Bugando Medical Centre from January 2008 to December 2010. Data collected were analyzed using SPSS computer software version 15.
Results:
A total of 104 patients with epistaxis were studied. Males were affected twice more than the females (2.7:1). Their mean age was 32.24 &#177; 12.54 years (range 4 to 82 years). The modal age group was 31-40 years. The commonest cause of epistaxis was trauma (30.8%) followed by idiopathic (26.9%) and hypertension (17.3%). Anterior nasal bleeding was noted in majority of the patients (88.7%). Non surgical measures such as observation alone (40.4%) and anterior nasal packing (38.5%) were the main intervention methods in 98.1% of cases. Surgical measures mainly intranasal tumor resection was carried out in 1.9% of cases. Arterial ligation and endovascular embolization were not performed. Complication rate was 3.8%. The overall mean of hospital stay was 7.2 &#177; 1.6 days (range 1 to 24 days). Five patients died giving a mortality rate of 4.8%.
Conclusion:
Trauma resulting from road traffic crush (RTC) remains the most common etiological factor for epistaxis in our setting. Most cases were successfully managed with conservative (non-surgical) treatment alone and surgical intervention with its potential complications may not be necessary in most cases and should be the last resort. Reducing the incidence of trauma from RTC will reduce the incidence of emergency epistaxis in our centre.</description>
        <link>http://www.biomedcentral.com/1472-6815/11/8</link>
                <dc:creator>Japhet Gilyoma</dc:creator>
                <dc:creator>Phillipo Chalya</dc:creator>
                <dc:source>BMC Ear, Nose and Throat Disorders 2011, null:8</dc:source>
        <dc:date>2011-09-05T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1472-6815-11-8</dc:identifier>
                                <prism:require>/content/figures/1472-6815-11-8-toc.gif</prism:require>
                <prism:publicationName>BMC Ear, Nose and Throat Disorders</prism:publicationName>
        <prism:issn>1472-6815</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>8</prism:startingPage>
        <prism:publicationDate>2011-09-05T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1472-6815/11/7">
        <title>Prevalence and psychopathological characteristics of depression in consecutive otorhinolaryngologic inpatients</title>
        <description>Background:
High prevalence of depression has been reported in otorhinolaryngologic patients (ORL). However, studies using a semi-structured interview to determine the prevalence of depression in ORL are lacking. Therefore the present study sought to determine the depression prevalence in ORL applying a semi-structured diagnostic interview and to further characterize the pathopsychological and demographic characteristics of depression in these patients.
Methods:
One-hundred inpatients of the otorhinolaryngologic department of a German university hospital participated voluntarily (age M = 38.8 years, SD = 13.9; 38.0% female). Depression was assessed using a clinical interview in which the International Diagnostic Checklist for depression (IDCL) was applied. Patients completed the Brief Symptom Inventory (BSI) which constitutes three composite scores and nine symptom scales and the Beck Depression Inventory (BDI). Multivariate analyses of variance, correlations and effect sizes were conducted.
Results:
A prevalence of depression of 21.0% was determined, 38.0% of the depressed patients were female. Depressed patients showed higher scores on the BSI-scales &quot;interpersonal sensitivity&quot;, &quot;depression&quot;, &quot;anxiety&quot;, &quot;phobic anxiety&quot; and &quot;psychoticism&quot; with medium effect sizes.
Conclusions:
High prevalence of depression was found which is in accordance with results of prior studies. Depressed patients showed higher psychological distress as compared to non-depressed patients. The results call for carrying on in engaging in depression research and routine depression screening in ORL.</description>
        <link>http://www.biomedcentral.com/1472-6815/11/7</link>
                <dc:creator>Thomas Forkmann</dc:creator>
                <dc:creator>Christine Norra</dc:creator>
                <dc:creator>Markus Wirtz</dc:creator>
                <dc:creator>Thomas Vehren</dc:creator>
                <dc:creator>Eftychia Volz-Sidiropoulou</dc:creator>
                <dc:creator>Martin Westhofen</dc:creator>
                <dc:creator>Siegfried Gauggel</dc:creator>
                <dc:creator>Maren Boecker</dc:creator>
                <dc:source>BMC Ear, Nose and Throat Disorders 2011, null:7</dc:source>
        <dc:date>2011-08-31T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1472-6815-11-7</dc:identifier>
                                <prism:require>/content/figures/1472-6815-11-7-toc.gif</prism:require>
                <prism:publicationName>BMC Ear, Nose and Throat Disorders</prism:publicationName>
        <prism:issn>1472-6815</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>7</prism:startingPage>
        <prism:publicationDate>2011-08-31T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1472-6815/11/6">
        <title>A Synchronous undifferentiated nasopharyngeal carcinoma and infiltrating ductal carcinoma of the breast successfully treated with induction chemotherapy followed by local control of both tumours: a case report.</title>
        <description>Background:
Multiple primary cancers have a low incidence particularly when cancers are synchronous. Few cases of synchronous head and neck cancer and breast carcinoma are reported in the literature.Case presentationWe report here an exceptional case of a 47 years old Moroccan woman presenting two synchronous cancers, the first in the nasopharynx and the second in the breast. The patient was treated successfully with a combined strategy associating chemotherapy, radiation therapy, and surgery. She remains disease free after 27 months of follow up.
Conclusions:
Treatment strategy in the case of multiple primary cancers remains controversial because of the variety of presentations; initial aggressive treatment reports good results.</description>
        <link>http://www.biomedcentral.com/1472-6815/11/6</link>
                <dc:creator>Mohamed Mesmoudi</dc:creator>
                <dc:creator>Tarik Mahfoud</dc:creator>
                <dc:creator>Nabil Ismaili</dc:creator>
                <dc:creator>Khadija Rami</dc:creator>
                <dc:creator>Meryem Kamouni</dc:creator>
                <dc:creator>Laila Jroundi</dc:creator>
                <dc:creator>Hassan Errihani</dc:creator>
                <dc:source>BMC Ear, Nose and Throat Disorders 2011, null:6</dc:source>
        <dc:date>2011-06-09T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1472-6815-11-6</dc:identifier>
                                <prism:require>/content/figures/1472-6815-11-6-toc.gif</prism:require>
                <prism:publicationName>BMC Ear, Nose and Throat Disorders</prism:publicationName>
        <prism:issn>1472-6815</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>6</prism:startingPage>
        <prism:publicationDate>2011-06-09T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1472-6815/11/5">
        <title>Signs and symptoms of temporomandibular joint disorders related to the degree of mouth opening and hearing loss.</title>
        <description>Background:
The temporomandibular joint is a unique bi-condylar joint involved in mastication and speech. Temporomandibular joint disorders (TMD) have a range of symptoms, including aural symptoms, and are present in approximately 75% of normal populations. The present study examined the relationship between signs and symptoms of TMD and mouth opening, gender, joint and aural symptoms, and hearing loss.
Methods:
The study involved 464 healthy Greek university students (156 men and 308 women) with a mean age of 19.6 years. Age, gender and maximum mouth opening was recorded. Mouth opening was measured using Vernier calipers. An anamnestic questionnaire was used to stratify the subjects into four groups based on TMD severity. Aural symptoms and an audiogram were recorded for each subject too. Data were analyzed using multifactor ANOVA, chi-square, t-test, Mann-Whitney and Kruskal-Wallis tests.
Results:
The overall incidence of TMD signs and symptoms was 73.3%. The incidence and severity was greater in females than males (p-value 0.0001 &lt; 0.05). The number of aural symptoms was associated to the TMD severity (p-value 0.0001 &lt; 0.05) as well as maximum mouth opening (p-value 0.004 &lt; 0.05). Audiometry showed that moderate and severe TMD was associated with hearing loss of median and low tones respectively (p-value 0.0001 &lt; 0.05). TMJ pain (p-value 0.0001 &lt; 0.05), TMJ ankylosis (p-value 0.0001 &lt; 0.05), bruxism (p-value 0.0001 &lt; 0.05) and ear itching (p-value 0.0001 &lt; 0.05) were also found to be statistically different between TMD and non-TMD subjects.
Conclusions:
TMD signs and symptoms were more common and severe in females than males. TMD severity is correlated with the degree of mouth opening and the number of aural symptoms. The absence or presence of mild TMD are associated with normal audiograms while moderate and severe TMD are related to hearing loss in median and low tones respectively. Bruxism, joint ankylosis, joint pain and ear itching were more common in TMD than non-TMD patients.</description>
        <link>http://www.biomedcentral.com/1472-6815/11/5</link>
                <dc:creator>Panagiotis Kitsoulis</dc:creator>
                <dc:creator>Aikaterini Marini</dc:creator>
                <dc:creator>Kalliopi Iliou</dc:creator>
                <dc:creator>Vasiliki Galani</dc:creator>
                <dc:creator>Aristides Zimpis</dc:creator>
                <dc:creator>Panagiotis Kanavaros</dc:creator>
                <dc:creator>Georgios Paraskevas</dc:creator>
                <dc:source>BMC Ear, Nose and Throat Disorders 2011, null:5</dc:source>
        <dc:date>2011-05-25T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1472-6815-11-5</dc:identifier>
                            <dc:title>Symptoms of temporomandibular joint disorders</dc:title>
                            <dc:description>The severity of temporomandibular joint disorders is associated with range of mouth opening, the number of aural symptoms, ear itching, temporomandibular joint ankylosis, temporomandibular joint pain, bruxism and qualitative and quantitative hearing loss.</dc:description>
                <prism:require>/content/figures/1472-6815-11-5-toc.gif</prism:require>
                <prism:publicationName>BMC Ear, Nose and Throat Disorders</prism:publicationName>
        <prism:issn>1472-6815</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>5</prism:startingPage>
        <prism:publicationDate>2011-05-25T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1472-6815/11/4">
        <title>Radiological Findings In Patients Undergoing Revision Endoscopic Sinus Surgery: A retrospective case series study</title>
        <description>Background:
Functional endoscopic sinus surgery (FESS) is now a well-established strategy for the treatment of chronic rhinosinusitis which has not responded to medical treatment. There is a wide variation in the practice of FESS by various surgeons within the UK and in other countries.ObjectivesTo identify anatomic factors that may predispose to persistent or recurrent disease in patients undergoing revision FESS.
Methods:
Retrospective review of axial and coronal CT scans of patients undergoing revision FESS between January 2005 and November 2008 in a tertiary referral centre in South West of England.
Results:
The CT scans of 63 patients undergoing revision FESS were reviewed. Among the patients studied, 15.9% had significant deviation of the nasal septum. Lateralised middle turbinates were present in 11.1% of the studied sides, and residual uncinate processes were identified in 57.1% of the studied sides. There were residual cells in the frontal recess in 96% of the studied sides. There were persistent other anterior and posterior ethmoidal cells in 92.1% and 96% of the studied sides respectively.
Conclusions:
Analysis of CT scans of patients undergoing revision FESS shows persistent structures and non-dissected cells that may be responsible for persistence or recurrence of rhinosinusitis symptoms. Trials comparing the outcome of conservative FESS techniques with more radical sinus dissections are required.</description>
        <link>http://www.biomedcentral.com/1472-6815/11/4</link>
                <dc:creator>Hisham Khalil</dc:creator>
                <dc:creator>Ahmed Eweiss</dc:creator>
                <dc:creator>Nicholas Clifton</dc:creator>
                <dc:source>BMC Ear, Nose and Throat Disorders 2011, null:4</dc:source>
        <dc:date>2011-05-07T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1472-6815-11-4</dc:identifier>
                                <prism:require>/content/figures/1472-6815-11-4-toc.gif</prism:require>
                <prism:publicationName>BMC Ear, Nose and Throat Disorders</prism:publicationName>
        <prism:issn>1472-6815</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>4</prism:startingPage>
        <prism:publicationDate>2011-05-07T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <cc:License rdf:about="http://creativecommons.org/licenses/by/2.0/">
        <cc:permits rdf:resource="http://creativecommons.org/ns#Reproduction" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#Distribution" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#DerivativeWorks" />
    </cc:License>
</rdf:RDF>

